Loading...

Upexi, Inc.

GRVINASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$4.95
$0.35(7.61%)
U.S. Market opens in 8h 28m

Upexi, Inc. Fundamental Analysis

Upexi, Inc. (GRVI) shows weak financial fundamentals with a PE ratio of -2.42, profit margin of -6.61%, and ROE of -1.20%. The company generates $0.0B in annual revenue with weak year-over-year growth of -67.77%.

Key Strengths

PEG Ratio-0.00
Current Ratio2.20

Areas of Concern

ROE-1.20%
Operating Margin-6.24%
Cash Position0.54%
We analyze GRVI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -673.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-673.8/100

We analyze GRVI's fundamental strength across five key dimensions:

Efficiency Score

Weak

GRVI struggles to generate sufficient returns from assets.

ROA > 10%
-45.92%

Valuation Score

Excellent

GRVI trades at attractive valuation levels.

PE < 25
-2.42
PEG Ratio < 2
-0.00

Growth Score

Weak

GRVI faces weak or negative growth trends.

Revenue Growth > 5%
-67.77%
EPS Growth > 10%
-24.43%

Financial Health Score

Moderate

GRVI shows balanced financial health with some risks.

Debt/Equity < 1
4.36
Current Ratio > 1
2.20

Profitability Score

Weak

GRVI struggles to sustain strong margins.

ROE > 15%
-119.69%
Net Margin ≥ 15%
-6.61%
Positive Free Cash Flow
No

Key Financial Metrics

Is GRVI Expensive or Cheap?

P/E Ratio

GRVI trades at -2.42 times earnings. This suggests potential undervaluation.

-2.42

PEG Ratio

When adjusting for growth, GRVI's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Upexi, Inc. at 6.18 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.18

EV/EBITDA

Enterprise value stands at 1.02 times EBITDA. This is generally considered low.

1.02

How Well Does GRVI Make Money?

Net Profit Margin

For every $100 in sales, Upexi, Inc. keeps $-6.61 as profit after all expenses.

-6.61%

Operating Margin

Core operations generate -6.24 in profit for every $100 in revenue, before interest and taxes.

-6.24%

ROE

Management delivers $-1.20 in profit for every $100 of shareholder equity.

-1.20%

ROA

Upexi, Inc. generates $-45.92 in profit for every $100 in assets, demonstrating efficient asset deployment.

-45.92%

Following the Money - Real Cash Generation

Operating Cash Flow

Upexi, Inc. generates limited operating cash flow of $-3.79M, signaling weaker underlying cash strength.

$-3.79M

Free Cash Flow

Upexi, Inc. generates weak or negative free cash flow of $-3.61M, restricting financial flexibility.

$-3.61M

FCF Per Share

Each share generates $-0.20 in free cash annually.

$-0.20

FCF Yield

GRVI converts -13.76% of its market value into free cash.

-13.76%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.42

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.18

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.72

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

4.36

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.20

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.20

vs 25 benchmark

ROA

Return on assets percentage

-0.46

vs 25 benchmark

ROCE

Return on capital employed

-0.61

vs 25 benchmark

How GRVI Stacks Against Its Sector Peers

MetricGRVI ValueSector AveragePerformance
P/E Ratio-2.4228.81 Better (Cheaper)
ROE-119.69%643.00% Weak
Net Margin-661.36%-44312.00% (disorted) Weak
Debt/Equity4.360.36 Weak (High Leverage)
Current Ratio2.204.50 Strong Liquidity
ROA-45.92%-17799.00% (disorted) Weak

GRVI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Upexi, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

16565.63%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-57134.38%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-5699.81%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ